Merck to buy Prometheus Biosciences for about 11 billion Reuters

April 16 (Reuters) – Merck & Co (MRK.N) said on Sunday it will buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, picking up a promising experimental treatment for ulcerative coliti… [+2693 chars]Read More